全文获取类型
收费全文 | 1326篇 |
免费 | 91篇 |
国内免费 | 17篇 |
专业分类
儿科学 | 21篇 |
妇产科学 | 2篇 |
基础医学 | 59篇 |
临床医学 | 56篇 |
内科学 | 772篇 |
皮肤病学 | 5篇 |
神经病学 | 4篇 |
特种医学 | 30篇 |
外国民族医学 | 4篇 |
外科学 | 47篇 |
综合类 | 102篇 |
现状与发展 | 1篇 |
预防医学 | 144篇 |
药学 | 97篇 |
中国医学 | 76篇 |
肿瘤学 | 14篇 |
出版年
2024年 | 4篇 |
2023年 | 84篇 |
2022年 | 95篇 |
2021年 | 130篇 |
2020年 | 115篇 |
2019年 | 138篇 |
2018年 | 101篇 |
2017年 | 73篇 |
2016年 | 71篇 |
2015年 | 39篇 |
2014年 | 148篇 |
2013年 | 86篇 |
2012年 | 56篇 |
2011年 | 81篇 |
2010年 | 31篇 |
2009年 | 36篇 |
2008年 | 51篇 |
2007年 | 43篇 |
2006年 | 20篇 |
2005年 | 18篇 |
2004年 | 3篇 |
2003年 | 7篇 |
2002年 | 4篇 |
排序方式: 共有1434条查询结果,搜索用时 31 毫秒
61.
62.
Flavia Agata Cimini Ilaria Barchetta Gea Ciccarelli Frida Leonetti Gianfranco Silecchia Caterina Chiappetta Claudio Di Cristofano Danila Capoccia Laura Bertoccini Valentina Ceccarelli Raffaella Carletti Antonio Fraioli Marco Giorgio Baroni Sergio Morini Maria Gisella Cavallo 《Diabetes/metabolism research and reviews》2021,37(1)
63.
64.
Ambrish Singh Salman Hussain Benny Antony 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(3):813-822
BackgroundNon-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable population that may be susceptible to more severe COVID-19. Moreover, not only the underlying NAFLD may influence the progression of COVID-19, but the COVID-19 may affect the clinical course of NAFLD as well. However, comprehensive evidence on clinical outcomes in patients with NAFLD is not well characterized.ObjectivesTo systematically review and meta-analysis the evidence on clinical outcomes in NAFLD patients with COVID-19.MethodsMEDLINE, EMBASE, and Cochrane Central were searched from inception through November 2020. Epidemiological studies assessing the clinical outcomes in COVID-19 patients with NAFLD were included. Newcastle-Ottawa Scale (NOS) was used to assess study quality. Generic inverse variance method using RevMan was used to determine the pooled estimates using the random-effects model.ResultsFourteen studies consisting of 1851 NAFLD patients, were included. Significant heterogeneity was observed among the studies, and studies were of moderate to high quality [mean, (range):8 (6, 8)]. For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI:2.24–3.02; p < 0.001) (studies,n:8), aOR for admission to ICU due to COVID-19 was 1.66 (95%CI:1.26–2.20; p < 0.001) (studies,n:2), and aOR for mortality for was 1.01 (95%CI:0.65–1.58; p = 0.96) (studies,n:2).ConclusionsAn increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to conclusively elucidate the impact of NAFLD in patients with COVID-19. 相似文献
65.
Salvatore Petta Giada Sebastiani Elisabetta Bugianesi Mauro Viganò Vincent Wai-Sun Wong Annalisa Berzigotti Anna Ludovica Fracanzani Quentin M. Anstee Fabio Marra Marco Barbara Vincenza Calvaruso Calogero Cammà Vito Di Marco Antonio Craxì Victor de Ledinghen 《Journal of hepatology》2018,68(4):878-885
66.
Assy N Bekirov I Mejritsky Y Solomon L Szvalb S Hussein O 《World journal of gastroenterology : WJG》2005,11(37):5834-5839
AIM: To evaluate the prevalence of genetic and acquired prothrombotic risk factors and their association with the extent of fibrosis and fatty infiltration in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: Forty-four patients with chronic hepatitis (28 men and 16 women, with mean age of 45±11 and 49±12 years, respectively) constituted the patient population of this study. The groups were divided as follows: 15 patients with fatty liver (FL); 15 with non-alcoholic steatohepatitis (NASH); 14 with chronic viral hepatitis (CH) diagnosed by histology and liver technetium scan or ultrasound; and 10 healthy individuals. Thrombophilic, coagulation factors and genetic mutations were diagnosed by standard hemostatic and molecular coagulation assays. RESULTS: Activated protein C (APC) resistance and protein S were the most prevalent thrombotic risk factors (6% and 10% in NAFLD vs 21% and 14% in CH; P<0.01 and P<0.05, respectively). One thrombotic risk factor was identified in 41% of patients (23% mild fibrosis, 18% severe fibrosis) and two thrombotic risk factors in 6% of patients with NAFLD and severe fibrosis. While no differences in APC ratio, lupus anticoagulant, fibrinogen, factor V Leiden, prothrombin, and MTHFR mutation were found. Protein S levels were significantly lower in NASH patients than in patients with FL alone (92±19 vs 106±2, P<0.01). Protein C levels were markedly higher in patients with NAFLD and mild or severe fibrosis as compared to the patients with CH, respectively (128±40 vs 96±14, P<0.001 or 129±36 CONCLUSION: Up to 46% of patients with NAFLD may have thrombotic risk factors, and the presence of thrombotic risk factors is correlated with the extent of hepatic fibrosis, suggesting a crucial role of the coagulation system in the pathogenesis of hepatic fibrosis. 相似文献
67.
Silvia Bondini Jillian Kallman Angela Wheeler Shivaani Prakash Terry Gramlich Daniel M Jondle Zobair M Younossi 《Liver international》2007,27(5):607-611
BACKGROUND: The impact of superimposed non-alcoholic fatty liver disease (NAFLD) is well established in patients with chronic hepatitis C (CH-C), but the impact in patients with chronic hepatitis B (CH-B) is less clear. Aim: This study aims to evaluate the prevalence of NAFLD in patients with CH-B and the association with viral and host factors, particularly in patients with metabolic syndrome (MS). DESIGN: Data from patients with CH-B was obtained from our databases. Patients with excessive alcohol use were excluded. Hepatitis B virus (HBV) genotyping by INNO-LIPA was available for some patients. The presence of MS was defined according to the Adult Treatment Panel III (ATP III). All biopsies were read by two hepatopathologists using Metavir, modified histologic activity index (MHAI), as well as a NAFLD pathologic protocol. Patients were classified as (1) those without NAFLD; (2) those with simple hepatic steatosis; (3) and those with superimposed non-alcoholic steatohepatitis (NASH). Factors associated with superimposed NAFLD, its subtypes, and hepatic fibrosis were also analysed. RESULTS: Subjects included 153 HBV patients [66% male, age 50.5+/-27.5 years, body mass index 24.7+/-3.7 kg/m(2), waist 83.2+/-10.9 cm; 8.5% Caucasian, 67% Asian, aspartate aminotransferase (AST) 63.2+/-88.2 IU/l, alanine aminotransferase (ALT) 98.6+/-164.6 IU/l, glucose 111.6+/-50.5 mg/dl, HBV-DNA 1.8 x 10(8)+/-1.9 x 10(6) copies/ml, 7% with MS, 13% with diabetes, 20% with arterial hypertension and 8.5% with dyslipidaemia]. Liver biopsy was available for 64 subjects [19% had superimposed NAFLD, 13% had superimposed NASH, 86% had some degree of fibrosis, and 39% had advanced fibrosis (Ishak >3)]. Patients with HBV and superimposed NASH were significantly older (55 vs. 42 years, P=0.008), more likely to have hypertension (63% vs. 15%, P=0.006) and dyslipidaemia (50% vs. 8%, P=0.006), and had a larger waist circumference (92 vs. 83 cm, P=0.03). The presence of fibrosis was associated with higher waist circumference (84 vs. 80 cm, P=0.03), higher HBV-DNA (1.9 x 10(8) vs. 5 x 10(6) copies/ml, P=0.005), and elevated ALT >40 IU/l (73.6% vs. 33.3%, P=0.02). CONCLUSIONS: The components of MS (obesity, hypertension, and dyslipidaemia) are associated with the presence of NASH in patients with CH-B. The presence of hepatic fibrosis seems to be associated with known host and viral factors as well as the presence of abdominal obesity. 相似文献
68.
69.
70.